GlassScriptPhysician profile
William J Mccann
NPI 1225095490
$1,036.52
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $191.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.16 | 2019-2020 | |
| Novo Nordisk INC | $135.17 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.93 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $94.27 | 2019-2020 | |
| Lilly USA, LLC | $85.17 | 2019-2020 | |
| Amgen INC. | $80.73 | 2019 | |
| Pfizer INC. | $68.43 | 2019-2020 | |
| Grifols USA, LLC | $65.12 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $49.31 | 2019-2020 | |
| Glaxosmithkline, LLC. | $26.83 | 2019 | |
| Abbvie INC. | $22.73 | 2019 | |
| Astellas Pharma US INC | $16.25 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.98 | 2019 | |
| Boston Scientific Corporation | $15.48 | 2019 | |
| Amarin Pharma, INC. | $14.44 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $13.86 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.30 | 2019 | |
| Horizon Therapeutics Plc | $11.98 | 2019 | |
| Edwards Lifesciences Corporation | $11.38 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mccann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.